Meeting
2021 ASCO Annual Meeting
Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab.
Authors
Khalid Jazieh
Cleveland Clinic Foundation, Cleveland, OH
Khalid Jazieh , Mohammadhadi Khorrami , Anas M. Saad , Mohamed M. Gad , Vidya Sankar Viswanathan , Pingfu Fu , Prabhakar Rajiah , Anant Madabhushi , Nathan A. Pennell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3054)
DOI
10.1200/JCO.2021.39.15_suppl.3054
Abstract #
3054
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.
First Author: George R. Simon
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo
Poster
2022 ASCO Annual Meeting
Texture-based CT radiomics distinguishes radiation and immunotherapy induced pneumonitis in stage III NSCLC.
First Author: Lukas Delasos